LONARDI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 1.300
EU - Europa 423
AS - Asia 226
AF - Africa 62
Totale 2.011
Nazione #
US - Stati Uniti d'America 1.285
IT - Italia 143
SG - Singapore 106
SE - Svezia 96
CN - Cina 78
GB - Regno Unito 50
DE - Germania 46
CI - Costa d'Avorio 33
BG - Bulgaria 32
TR - Turchia 16
VN - Vietnam 16
CA - Canada 15
NG - Nigeria 15
SN - Senegal 13
FI - Finlandia 12
RU - Federazione Russa 12
PL - Polonia 7
FR - Francia 6
HK - Hong Kong 6
CZ - Repubblica Ceca 4
NL - Olanda 3
AT - Austria 2
GR - Grecia 2
IN - India 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
UA - Ucraina 2
AL - Albania 1
EE - Estonia 1
EG - Egitto 1
JP - Giappone 1
MY - Malesia 1
Totale 2.011
Città #
Woodbridge 144
Fairfield 129
Chandler 123
Ann Arbor 116
Houston 108
Ashburn 54
Seattle 54
Wilmington 48
New York 47
Singapore 47
Santa Clara 46
Boardman 42
Cambridge 40
Abidjan 33
Sofia 32
Florence 29
Princeton 28
London 27
Lawrence 26
Medford 20
Ogden 20
Beijing 19
Pisa 18
Serra 18
Lancaster 16
Lagos 15
Dakar 13
Istanbul 12
Bremen 11
Ottawa 11
San Diego 11
Dearborn 10
Des Moines 10
Council Bluffs 9
Shanghai 9
Quanzhou 7
Warsaw 7
Frankfurt am Main 6
Hong Kong 6
Verona 6
Düsseldorf 5
Kent 5
Los Angeles 5
Redwood City 5
Rome 5
Dong Ket 4
Fuzhou 4
Nanjing 4
Norwalk 4
Seacroft 4
Boulder 3
Changsha 3
Cislago 3
Detroit 3
Milan 3
Munich 3
Shenyang 3
Brno 2
Canino 2
Guangzhou 2
Lappeenranta 2
Marina di Ravenna 2
Marseille 2
Modugno 2
Noventa di Piave 2
Phoenix 2
Pistoia 2
Positano 2
Redmond 2
San Giuliano Terme 2
Toronto 2
Turin 2
Vicopisano 2
Vienna 2
Washington 2
Amsterdam 1
Bazhou 1
Berlingo 1
Bologna 1
Boydton 1
Bratislava 1
Bucharest 1
Cairo 1
Capannori 1
Chengdu 1
Città della Pieve 1
Dallas 1
Eagleville 1
Edmonton 1
Fort Worth 1
Gallarate 1
Genoa 1
Hamilton 1
Hangzhou 1
Hanoi 1
Hebei 1
Indore 1
Izmir 1
Jiaxing 1
Kunming 1
Totale 1.554
Nome #
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 130
null 129
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 122
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 121
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 112
null 111
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 100
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 91
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 87
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 86
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 84
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 82
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 65
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 52
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 51
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 44
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 43
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 42
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 40
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 35
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 35
Epstein-Barr virus associated gastric dysplasia: a new rare entity? 35
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 33
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 31
The added value of baseline circulating tumor DNA profiling in patients with molecularly hyperselected, left-sided metastatic colorectal cancer 28
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 27
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 26
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 26
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 25
Gastric cancer: Translating novels concepts into clinical practice 25
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 24
Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study 21
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action 16
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 14
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 11
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 11
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 11
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 10
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial 10
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 10
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 9
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 9
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 9
Totale 2.083
Categoria #
all - tutte 8.309
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.309


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020208 0 0 0 0 38 39 30 25 28 29 13 6
2020/2021116 10 5 5 7 7 3 17 4 14 16 12 16
2021/2022209 2 2 0 6 25 38 5 6 14 22 19 70
2022/2023435 33 76 41 30 49 36 7 24 92 1 38 8
2023/2024253 15 20 43 9 24 42 22 8 7 7 30 26
2024/2025259 11 88 33 62 65 0 0 0 0 0 0 0
Totale 2.083